Health Care • Biotechnology: Pharmaceutical Preparations
$2.55 ▼ -0.14
(-5.27%)
MKT CAP: $15.5M • VOL: 11.2K
52W L $2 52W H $8
ROARABLE / RQD
E • 30/100
PIOTROSKI
1 / 9
NCEL // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$2.6M | -$2.1M | -$3.0M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$8.3M | -$7.2M | -$3.3M |
| EBITDA (Normalized) | -$2.6M | -$2.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$2.8M | -$1.1M | -$3.4M |
| Capital Expenditures (CapEx) | $8.0K | $6.0K | — |
| Free Cash Flow (FCF) | -$2.8M | -$1.1M | -$3.4M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -40.1% | -45.0% | — |
| Cash & Short-Term Equivalents | $2.2M | $650.0K | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $7.3M | -$8.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NCEL.